The KRAS oncogene is mutated in approximately 35%-45% of colorectal cancers, and KRAS mutational status testing has been highlighted in recent years. The most frequent mutations in this gene, point substitutions in codons 12 and 13, were validated as negative predictors of response to anti-...
László, L., Kurilla, A., Takács, T., Kudlik, G., Koprivanacz, K., Buday, L., & Vas, V. (2021). Recent Updates on the Significance of KRAS Mutations in Colorectal Cancer Biology. Cells, 10(3), 667. https://doi.org/10.3390/cells10030667 Li, S., Balmain, A., & Counter,...
FULL PAPER British Journal of Cancer (2013) 108, 1757–1764 | doi: 10.1038/bjc.2013.118 Keywords: colorectal cancer; KRAS; survival; mortality; microsatellite instability; BRAF KRAS-mutation status in relation to colorectal cancer survival: the joint impact of correlated tumour markers A I Phipps*...
TheRASgene family is among the most studied and best characterized of the known cancer-related genes. Of the three human ras isoforms,KRASis the most frequently altered gene, with mutations occurring in 17%–25% of all cancers. In particular, approximately 30%–40% of colon cancers harbor a...
Abstract 5424: Therapeutic targeting of KRAS mutation-driven tumor progression in colorectal cancer KRAS is the most frequently altered gene in colorectal cancer (CRC), with mutations occurring in 30-40% of colorectal cancer. Although KRAS mutation is associated with poor prognosis and resistance to ...
KRAS mutation is responsible for 40–50% of colorectal cancers (CRCs). RNA-seq data and bioinformatics methods were used to analyze the transcriptional profiles of KRAS mutant (mtKRAS) in comparison with the wild-type (wtKRAS) cell lines, followed by in-
Approximately 30% to 50% of colorectal tumors are known to have a mutated (abnormal) KRAS gene, indicating that up to 50% of patients with colorectal cancer (CRC) might respond to anti-epidermal growth factor receptor (EGFR) antibody therapy. However, 40
Demographic trends and KRAS/BRAFV600E mutations in colorectal cancer patients of South China: A single‐site reportdoi:10.1002/ijc.31973KRAS mutationBRAF mutationtubular adenocarcinomademographic trendscolorectal cancerThe incidence of colorectal cancer (CRC) is increasing in China. Here, we aimed to ...
KRAS mutational analysis is a genetic test used in clinical practice for determining the status of the KRAS gene (wild type or mutant) in tumors from patients with metastatic colorectal cancer (CRC). Persons whose tumors are wild type may respond to therapies cetuximab (Erbitux) or panitumumab ...
The mutation of the KRAS (Kirsten rat sarcoma virus) gene is a prevalent genetic alteration in metastatic colorectal cancer (mCRC). According to previous research, this mutation significantly affects clinical outcomes and quality of life (QOL). This research investigated the association between KRAS ...